# A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

> **NCT06978647** · PHASE1 · RECRUITING · sponsor: **China Immunotech (Beijing) Biotechnology Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)
- Systemic Sclerosis (SSc)
- Inflammatory Myopathy
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Antiphospholipid Syndrome (APS)
- Rheumatoid Arthritis (RA)
- IgG4-Related Diseases
- Sjogren's Syndrome

## Interventions

- **DRUG:** YTS109 cell

## Key facts

- **NCT ID:** NCT06978647
- **Lead sponsor:** China Immunotech (Beijing) Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-19
- **Primary completion:** 2026-05-19
- **Final completion:** 2027-05-19
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06978647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06978647, "A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06978647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*